The global clinical trial equipment & ancillary solutions market size was exhibited at USD 2.99 billion in 2023 and is projected to hit around USD 7.01 billion by 2033, growing at a CAGR of 8.9% during the forecast period 2024 to 2033.
Report Coverage | Details |
Market Size in 2024 | USD 3.26 Billion |
Market Size by 2033 | USD 7.01 Billion |
Growth Rate From 2024 to 2033 | CAGR of 8.9% |
Base Year | 2023 |
Forecast Period | 2024-2033 |
Segments Covered | Product, Phase, Region |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
Key Companies Profiled | Ancillare, LP; Imperial CRS, Inc.; Woodley Equipment Company Ltd.; Thermo Fisher Scientific, Inc.; Parexel International (MA) Corporation; Emsere (MediCapital Rent); Quipment SAS; IRM; Marken; Myonex; Yourway |
The global market has witnessed critical growth due to increasing R&D investments, the growing need for clinical trials, and the rapid growth of pharmaceutical and medical industries.
The COVID-19 outbreak temporarily hindered the process of clinical trials in 2020 due to lockdowns enforced by governments, which impacted the market negatively. However, rising demand for effective COVID-19 treatments and other disorders led to a growth in the number of trials. Companies and government authorities are launching clinical trial initiatives for COVID-19. For instance, in July 2023, the National Institutes of Health introduced the RECOVER Initiative, targeting long-COVID clinical trials. Thus, the demand for equipment and ancillary solutions is expected to increase significantly with rising number of initiatives.
As the number of clinical trials increases, more resources are needed for conducting those trails, including equipment, ancillary supplies, and drugs. Ancillary supplies comprise all objects essential to conduct a study, such as surgical knives, syringes, swabs, gloves, and any other entities that patients and medical personnel require to administer medications and examine the efficacy and safety parameters under investigation.
Sourcing instruments & ancillary objects for clinical trials involve more than just procurement. It requires an in-depth knowledge of the study’s design and prerequisites, as well as relentless & proactive planning to ensure that the most pertinent tools and supplies are purchased at the proper time and an appropriate price. A combination of internal knowledge and external help is suggested in managing intricacies of equipment and ancillary supply, logistics, restocking, and expiry management.
Additionally, increased investments in R&D and the adoption of virtual clinical trials due to the COVID-19 pandemic have boosted industry growth. Furthermore, there is a tremendous upsurge in the number of studies undertaken for COVID-19, which is anticipated to enhance industry growth. For instance, according to an article by the U.S. Department of Health & Human Services in September 2023, the Strategies and Treatments for Respiratory Infections and Viral Emergencies (STRIVE), part of the global clinical trials consortium, would register about 1,500 individuals at research locations globally to test immune modulation method for hospitalized COVID-19 patients. Such trials and a growing interest of industry participants in clinical studies are expected to boost growth in the coming years.
Market growth stage is high, and the pace of the market growth is accelerating. The clinical trial equipment & ancillary solutions industry is characterized by a moderate degree of innovation due to rapid technological advancements, such as adoption of machine learning and AI in clinical trial platforms. Companies are entering the market and bringing novel technologies and platforms, which is expected to drive industrial innovations.
For instance, in November 2023, pharmaceutical giant AstraZeneca introduced the health technology business Evinova to enhance clinical trial processes. It offers digital technology tools to streamline clinical trial design and delivery to decrease time and costs in medicine development. This business would utilize artificial intelligence and machine learning to help clinical teams craft optimal studies. Furthermore, in October 2023, H1 introduced GenosAI, a new generative AI tool implanted into Trial Landscape, the compnay’s clinical trial intelligence platform, to scrutinize and respond to complicated queries.
The market is characterized by a moderate level of merger and acquisition (M&A) activities among leading players. This is due to several factors, including the desire to gain a competitive advantage in this industry and the need to consolidate in a rapidly growing market. Major industry participants are acquiring firms providing advanced services and solutions for clinical studies.
For instance, in October 2022, Myonex, a major clinical trial supply organization, acquired the clinical trial and packaging business of the Germany-based organization, Hubertus Apotheke. This acquisition is expected to support the capabilities and resources for both sourcing and packaging, including decentralized trials. Such acquisitions are expected to propel industry growth in the coming years.
Furthermore, industry participants are focusing on increasing their presence in several regions and improving access to instruments needed during clinical studies globally. For instance, in December 2022, Catalent announced the completion of the expansion of its clinical supply facility in Shanghai, China. With this expansion, the company increased the facility by about 30,000 sq. ft., adding refrigerated and deep-frozen storage and extended secondary packaging capacities. Thus, regional expansions by the major players are expected to improve access to these products.
The supply/logistics segment accounted for a dominant revenue share of 40.0% in 2023. As clinical trials have become more global and diverse, they require a proper cold-chain logistics system to maintain the integrity of temperature-sensitive drugs. Fluctuation in rules & regulations in emerging markets is expected to boost the need for supply/logistic services during the forecast period. Furthermore, presence of companies such as AKESA PTY LTD, Movianto, Parexel International (MA) Corporation., and Oximio offering supply and logistics solutions is expected to propel segment growth in the coming years.
The sourcing segment is anticipated to witness strong growth through 2033. Owing to the rising intricacy of clinical trials, the quantity of tools and ancillary supplies needed, as well as the number of suppliers required has risen substantially. The challenge of ensuring that supplies reach sites in a cost-effective manner for worldwide research has increased. With sourcing and distribution expertise, there is a single point of contact to supply and transport equipment and ancillary supplies worldwide. This streamlined and coordinated procedure removes the strain on teams conducting trials and facilities.
The phase III segment dominated the market in 2023 and is expected to maintain its dominance through 2033. Investigations in phase III are more complex than those in earlier phases. Even though the number of medications in this phase is relatively minimal, intricacies associated with this stage are immense. In addition, failure rates are also more as the research design and sample size require accurate dosing at an ideal level. This leads to human and economic damage, and most failures are generated by non-compliance with safety provisions. Such a scenario is likely to boost the demand for effective supply chain and logistics, which is projected to boost market growth over the coming years.
On the other hand, the phase I segment is projected to witness the highest growth rate over the forecast period due to the increasing number of pharmaceutical companies that are focusing on the development of novel therapeutics for rare diseases. Growth in the number of CROs globally is another factor supporting the adoption of phase I clinical trials to boost the rapid development of drugs.
North America dominated the clinical trial equipment & ancillary solutions market with a 40.15% revenue share in 2023. This dominance is attributed to the fact that most pharmaceutical businesses are located in the U.S. and perform most of their business in this region. Favorable regulatory policies, the introduction of technologically advanced products by market players, and increasing investments by pharmaceutical firms are expected to drive regional market growth during the forecast period. Companies operating in this industry are expanding their presence in the U.S. For instance, in March 2023, Almac Group invested USD 65 million to expand its supply-chain services for clinical trials in Montgomery County, Pennsylvania. Such expansions are expected to boost regional growth.
Asia Pacific is anticipated to witness fastest growth in the clinical trial equipment and ancillary solutions market. Asia Pacific has become a hotspot for performing clinical trials on account of inexpensive study costs, ease of regulatory compliance, an increasing patient population in this region, and the increasing presence of elite clinical institutions that are functioning as sites.
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global clinical trial equipment & ancillary solutions market.
Product
Phase
By Region
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Phase
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Phase outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Clinical Trial Equipment & Ancillary Solutions Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Evolving Clinical Trials Needs
3.2.1.2. Rising Investment in R&D
3.2.1.3. Growing pharmaceutical & Medical Devices industry
3.2.2. Market restraint analysis
3.2.2.1. Rising Cost of Clinical Trials
3.3. Clinical Trial Equipment & Ancillary Solutions Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.2. PESTEL Analysis
Chapter 4. Clinical Trial Equipment & Ancillary Solutions Market: Product Estimates & Trend Analysis
4.1. Product Market Share, 2024 & 2033
4.2. Segment Dashboard
4.3. Global Clinical Trial Equipment & Ancillary Solutions Market, by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following:
4.4.1. Sourcing
4.4.1.1. Sourcing market estimates and forecasts, 2021 - 2033
4.4.1.2. Procurement
4.4.1.2.1. Procurement market estimates and forecasts, 2021 - 2033
4.4.1.2.2. Equipment
4.4.1.2.2.1. Equipment market estimates and forecasts, 2021 - 2033
4.4.1.2.3. Ancillaries
4.4.1.2.3.1. Ancillaries market estimates and forecasts, 2021 - 2033
4.4.1.3. Rental
4.4.1.3.1. Rental market estimates and forecasts, 2021 - 2033
4.4.1.3.1.1. Equipment market estimates and forecasts, 2021 - 2033
4.4.1.3.2. Ancillaries
4.4.1.3.2.1. Ancillaries market estimates and forecasts, 2021 - 2033
4.4.2. Supply/ Logistics
4.4.2.1. Supply/logistics market estimates and forecasts, 2021 - 2033
4.4.2.2. Transportation
4.4.2.2.1. Transportation market estimates and forecasts, 2021 - 2033
4.4.2.3. Packaging
4.4.2.3.1. Packaging market estimates and forecasts, 2021 - 2033
4.4.2.4. Others
4.4.2.4.1. Others market estimates and forecasts, 2021 - 2033
4.4.3. Service
4.4.3.1. Service market estimates and forecasts, 2021 - 2033
4.4.3.2. Calibrations
4.4.3.2.1. Calibrations market estimates and forecasts, 2021 - 2033
4.4.3.3. Equipment Servicing
4.4.3.3.1. Equipment servicing market estimates and forecasts, 2021 - 2033
4.4.3.4. Others
4.4.3.4.1. Others market estimates and forecasts, 2021 - 2033
4.4.4. Others
4.4.4.1. Others market estimates and forecasts, 2021 - 2033
Chapter 5. Clinical Trial Equipment & Ancillary Solutions Market: Phase Estimates & Trend Analysis
5.1. Phase Market Share, 2024 & 2033
5.2. Segment Dashboard
5.3. Global Clinical Trial Equipment & Ancillary Solutions Market, by Phase Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following:
5.4.1. Phase I
5.4.1.1. Phase I market estimates and forecasts, 2021 - 2033
5.4.2. Phase II
5.4.2.1. Phase II market estimates and forecasts, 2021 - 2033
5.4.3. Phase III
5.4.3.1. Phase III market estimates and forecasts, 2021 - 2033
5.4.4. Phase IV
5.4.4.1. Phase IV market estimates and forecasts, 2021 - 2033
Chapter 6. Clinical Trial Equipment & Ancillary Solutions Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2033
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. Market Size & Forecasts and Trend Analysis, 2018 to 2030:
6.5. North America
6.5.1. U.S.
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework
6.5.1.3. Competitive scenario
6.5.1.4. U.S. market estimates and forecasts, 2021 - 2033
6.5.2. Canada
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework
6.5.2.3. Competitive scenario
6.5.2.4. Canada market estimates and forecasts, 2021 - 2033
6.6. Europe
6.6.1. UK
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework
6.6.1.3. Competitive scenario
6.6.1.4. UK market estimates and forecasts, 2021 - 2033
6.6.2. Germany
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework
6.6.2.3. Competitive scenario
6.6.2.4. Germany market estimates and forecasts, 2021 - 2033
6.6.3. France
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework
6.6.3.3. Competitive scenario
6.6.3.4. France market estimates and forecasts, 2021 - 2033
6.6.4. Italy
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework
6.6.4.3. Competitive scenario
6.6.4.4. Italy market estimates and forecasts, 2021 - 2033
6.6.5. Spain
6.6.5.1. Key country dynamics
6.6.5.2. Regulatory framework
6.6.5.3. Competitive scenario
6.6.5.4. Spain market estimates and forecasts, 2021 - 2033
6.6.6. Norway
6.6.6.1. Key country dynamics
6.6.6.2. Regulatory framework
6.6.6.3. Competitive scenario
6.6.6.4. Norway market estimates and forecasts, 2021 - 2033
6.6.7. Sweden
6.6.7.1. Key country dynamics
6.6.7.2. Regulatory framework
6.6.7.3. Competitive scenario
6.6.7.4. Sweden market estimates and forecasts, 2021 - 2033
6.6.8. Denmark
6.6.8.1. Key country dynamics
6.6.8.2. Regulatory framework
6.6.8.3. Competitive scenario
6.6.8.4. Denmark market estimates and forecasts, 2021 - 2033
6.7. Asia Pacific
6.7.1. Japan
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework
6.7.1.3. Competitive scenario
6.7.1.4. Japan market estimates and forecasts, 2021 - 2033
6.7.2. China
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework
6.7.2.3. Competitive scenario
6.7.2.4. China market estimates and forecasts, 2021 - 2033
6.7.3. India
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework
6.7.3.3. Competitive scenario
6.7.3.4. India market estimates and forecasts, 2021 - 2033
6.7.4. Australia
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework
6.7.4.3. Competitive scenario
6.7.4.4. Australia market estimates and forecasts, 2021 - 2033
6.7.5. South Korea
6.7.5.1. Key country dynamics
6.7.5.2. Regulatory framework
6.7.5.3. Competitive scenario
6.7.5.4. South Korea market estimates and forecasts, 2021 - 2033
6.7.6. Thailand
6.7.6.1. Key country dynamics
6.7.6.2. Regulatory framework
6.7.6.3. Competitive scenario
6.7.6.4. Thailand market estimates and forecasts, 2021 - 2033
6.8. Latin America
6.8.1. Brazil
6.8.1.1. Key country dynamics
6.8.1.2. Regulatory framework
6.8.1.3. Competitive scenario
6.8.1.4. Brazil market estimates and forecasts, 2021 - 2033
6.8.2. Mexico
6.8.2.1. Key country dynamics
6.8.2.2. Regulatory framework
6.8.2.3. Competitive scenario
6.8.2.4. Mexico market estimates and forecasts, 2021 - 2033
6.8.3. Argentina
6.8.3.1. Key country dynamics
6.8.3.2. Regulatory framework
6.8.3.3. Competitive scenario
6.8.3.4. Argentina market estimates and forecasts, 2021 - 2033
6.8.4. Colombia
6.8.4.1. Key country dynamics
6.8.4.2. Regulatory framework
6.8.4.3. Competitive scenario
6.8.4.4. Colombia market estimates and forecasts, 2021 - 2033
6.9. MEA
6.9.1. South Africa
6.9.1.1. Key country dynamics
6.9.1.2. Regulatory framework
6.9.1.3. Competitive scenario
6.9.1.4. South Africa market estimates and forecasts, 2021 - 2033
6.9.2. Saudi Arabia
6.9.2.1. Key country dynamics
6.9.2.2. Regulatory framework
6.9.2.3. Competitive scenario
6.9.2.4. Saudi Arabia market estimates and forecasts, 2021 - 2033
6.9.3. UAE
6.9.3.1. Key country dynamics
6.9.3.2. Regulatory framework
6.9.3.3. Competitive scenario
6.9.3.4. UAE market estimates and forecasts, 2021 - 2033
6.9.4. Kuwait
6.9.4.1. Key country dynamics
6.9.4.2. Regulatory framework
6.9.4.3. Competitive scenario
6.9.4.4. Kuwait market estimates and forecasts, 2021 - 2033
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2023
7.3.4. Ancillare, LP
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Imperial CRS, Inc.
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. Woodley Equipment Company Ltd.
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Thermo Fisher Scientific, Inc.
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Parexel International (MA) Corporation
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Emsere (MediCapital Rent)
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Quipment SAS
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. IRM
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. Marken
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
7.3.13. Myonex
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Product benchmarking
7.3.13.4. Strategic initiatives
7.3.14. Yourway
7.3.14.1. Company overview
7.3.14.2. Financial performance
7.3.14.3. Product benchmarking
7.3.14.4. Strategic initiatives